Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report
Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%–60% of ET patients harbor a JAK2 V617F mutation. This...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-08-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1658456/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849225265822040064 |
|---|---|
| author | Minghui Du Minghui Du Yinbao Hu Zhigang Liang Zhigang Liang Zhigang Liang |
| author_facet | Minghui Du Minghui Du Yinbao Hu Zhigang Liang Zhigang Liang Zhigang Liang |
| author_sort | Minghui Du |
| collection | DOAJ |
| description | Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%–60% of ET patients harbor a JAK2 V617F mutation. This mutation drives constitutive JAK kinase activation, promoting megakaryocyte proliferation and platelet production, while potentially activating inflammatory pathways and damaging vascular endothelium. We report a case of a JAK2 V617F-positive ET patient (sporadic presentation) who successfully underwent carotid artery stenting (CAS) for symptomatic internal carotid artery (ICA) stenosis. A 66-year-old male with known JAK2 V617F-positive ET presented with transient slurred speech and right-sided facial droop with mouth deviation. Magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) revealed an acute cerebral infarction in the right basal ganglia and corona radiata, along with right ICA stenosis. Aggressive perioperative platelet and inflammation control, employing hydroxyurea, aspirin, and ticagrelor, was instrumental in mitigating the heightened thrombosis risk associated with the JAK2 V617F mutation. This case underscores that ET patients with the JAK2 V617F mutation face a substantial risk of thrombotic recurrence. It highlights the critical importance of rigorous preoperative platelet control, personalized antiplatelet therapy guided by pharmacogenomic principles, and multidisciplinary management in high-risk ET patients undergoing CAS. |
| format | Article |
| id | doaj-art-8a3b3382b39b4d8da7b41af4771fc2e4 |
| institution | Kabale University |
| issn | 2297-055X |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj-art-8a3b3382b39b4d8da7b41af4771fc2e42025-08-25T05:26:17ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2025-08-011210.3389/fcvm.2025.16584561658456Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case reportMinghui Du0Minghui Du1Yinbao Hu2Zhigang Liang3Zhigang Liang4Zhigang Liang5Department of Neurology, Yuhuangding Hospital Affiliated to Qingdao University, Yantai, ChinaThe Second Clinical Medical College of Binzhou Medical University, Yantai, ChinaDepartment of Neurology, Yuhuangding Hospital Affiliated to Qingdao University, Yantai, ChinaDepartment of Neurology, Yuhuangding Hospital Affiliated to Qingdao University, Yantai, ChinaShandong Provincial Key Laboratory of Neuroimmune Interaction and Regulation, Yantai, ChinaNational Clinical Medical Research Center for Neurological Diseases Regional Subcenter, Yantai, ChinaEssential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by abnormal megakaryocyte proliferation and a markedly elevated platelet count, which predisposes patients to thrombotic or hemorrhagic events. Approximately 50%–60% of ET patients harbor a JAK2 V617F mutation. This mutation drives constitutive JAK kinase activation, promoting megakaryocyte proliferation and platelet production, while potentially activating inflammatory pathways and damaging vascular endothelium. We report a case of a JAK2 V617F-positive ET patient (sporadic presentation) who successfully underwent carotid artery stenting (CAS) for symptomatic internal carotid artery (ICA) stenosis. A 66-year-old male with known JAK2 V617F-positive ET presented with transient slurred speech and right-sided facial droop with mouth deviation. Magnetic resonance imaging/magnetic resonance angiography (MRI/MRA) revealed an acute cerebral infarction in the right basal ganglia and corona radiata, along with right ICA stenosis. Aggressive perioperative platelet and inflammation control, employing hydroxyurea, aspirin, and ticagrelor, was instrumental in mitigating the heightened thrombosis risk associated with the JAK2 V617F mutation. This case underscores that ET patients with the JAK2 V617F mutation face a substantial risk of thrombotic recurrence. It highlights the critical importance of rigorous preoperative platelet control, personalized antiplatelet therapy guided by pharmacogenomic principles, and multidisciplinary management in high-risk ET patients undergoing CAS.https://www.frontiersin.org/articles/10.3389/fcvm.2025.1658456/fullessential thrombocythemiaJAK2 v617F mutationsymptomatic internal carotid artery stenosiscarotid artery stentingdual antiplatelet therapy |
| spellingShingle | Minghui Du Minghui Du Yinbao Hu Zhigang Liang Zhigang Liang Zhigang Liang Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report Frontiers in Cardiovascular Medicine essential thrombocythemia JAK2 v617F mutation symptomatic internal carotid artery stenosis carotid artery stenting dual antiplatelet therapy |
| title | Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report |
| title_full | Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report |
| title_fullStr | Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report |
| title_full_unstemmed | Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report |
| title_short | Carotid artery stenting in JAK2 V617F-positive essential thrombocythemia with symptomatic internal carotid artery stenosis: a case report |
| title_sort | carotid artery stenting in jak2 v617f positive essential thrombocythemia with symptomatic internal carotid artery stenosis a case report |
| topic | essential thrombocythemia JAK2 v617F mutation symptomatic internal carotid artery stenosis carotid artery stenting dual antiplatelet therapy |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2025.1658456/full |
| work_keys_str_mv | AT minghuidu carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport AT minghuidu carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport AT yinbaohu carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport AT zhigangliang carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport AT zhigangliang carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport AT zhigangliang carotidarterystentinginjak2v617fpositiveessentialthrombocythemiawithsymptomaticinternalcarotidarterystenosisacasereport |